Aim: Follow-up strategies for high-grade bone sarcomas have been optimized to facilitate early detection of local recurrence and distant metastasis. The ideology is that early detection enables early treatment presuming better survival. However, the clinical value for each individual patient remains questionable. This study aims to evaluate oncological events after initial treatment in order to assess current follow-up strategies for high-grade bone sarcomas in the Netherlands.
Patients And Methods: A retrospective cohort study was conducted based on a national registry. All cases were retrieved from the Netherlands Cancer Registry. Our study consisted of 393 patients treated between 2007 and 2011 with complete follow-up data. Baseline characteristics were analysed for all entities. Local recurrence and distant metastasis was analysed along with overall survival for high-grade chondrosarcoma, high-grade osteosarcoma, Ewing sarcoma and chordoma.
Results: Median follow-up was 8,3 years for high-grade chondrosarcoma, 4,9 for high-grade osteosarcoma, 3,8 for Ewing sarcoma and 7,5 for chordoma. Median time to local recurrence and distant metastasis was 1,2 years for high-grade osteosarcoma and 1,5 years for Ewing sarcoma. For high-grade osteosarcoma with localized disease at presentation, 0.09 new distant metastatic events per patient per year were seen after five years of follow-up with 11,1 patients needed to follow-up for any event. Five-year overall survival was 60,0% for high-grade chondrosarcoma, 50,0% for high-grade osteosarcoma, 45,3% for Ewing sarcoma and 71,4% for chordoma.
Conclusions: This nationwide study shows a plateau in local recurrences and distant metastatic events after four years of treatment for patients with high-grade osteosarcoma and Ewing sarcoma. Due to a lack of reliable evidence however, we were not able to provide additional guidance on follow-up intervals and duration. Collaborative research with larger groups is needed in order to provide a solid scientific recommendation for follow-up in the heterogenous patient population with bone sarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791116 | PMC |
| http://dx.doi.org/10.1016/j.jbo.2022.100466 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Update on Conventional Osteosarcoma.
Rev Bras Ortop (Sao Paulo)
December 2024
Grupo de Oncologia Pediátrico, Hospital das Clínicas, Belo Horizonte, MG, Brasil.
Conventional osteosarcoma is a high-grade malignant tumor characterized by the production of osteoid matrix by malignant osteoblasts. It typically affects the long bones of children and adolescents. Treatment includes systemic chemotherapy and a local surgical approach with wide resection.
View Article and Find Full Text PDFRare presentation of Ewing's sarcoma underscores the diagnostic challenges in atypical cases.
BMJ Case Rep
December 2024
Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India.
Article Synopsis
- A young female patient experienced worsening right-sided chest pain and high-grade fever over 15 days, prompting a medical evaluation.
- Physical exams showed tenderness and reduced air entry in her right lung, leading to imaging that revealed a pleural effusion and a chest wall mass.
- After testing, instead of tuberculosis, the mass was diagnosed as Ewing's sarcoma, atypical for its usual presentation, highlighting the complexities of diagnosing rare conditions in TB-endemic areas.
Malignant Bone-Forming Neoplasm With NIPBL::BEND2 Fusion.
Genes Chromosomes Cancer
November 2024
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Conventional high-grade osteosarcomas are characterized by aggressive radiologic features, cytologic pleomorphism, and complex genomics. However, rare examples of osteosarcomas remain challenging due to unusual histology, such as sclerosing or osteoblastoma-like features, which may require molecular confirmation of their complex genetic alterations. We have encountered such a case in a 17-year-old man, who presented with a third metatarsal sclerotic bone lesion, found incidentally in the work-up of a foot trauma.
View Article and Find Full Text PDFThe Interplay Between the Oncogene and Ribosomal Proteins in Osteosarcoma Onset and Progression: Potential Mechanisms and Indication of Candidate Therapeutic Targets.
Int J Mol Sci
November 2024
Center for Applied Biomedical Research (CRBA), Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy.
High-grade osteosarcoma (OS) is the most common primary bone tumor mainly affecting children and young adults. First-line treatment consists of neo-adjuvant chemotherapy with doxorubicin, cisplatin, and methotrexate and surgery. The mean long-term survival rate for localized disease at diagnosis is 65-70%, dropping down to 20% when metastases are present at diagnosis.
View Article and Find Full Text PDFPrognostic Significance of Microvessel Density and Hypoxic Markers in Canine Osteosarcoma: Insights into Angiogenesis and Tumor Aggressiveness.
Animals (Basel)
November 2024
Department of Veterinary Sciences, University of Turin, 10095 Grugliasco, Italy.
Canine osteosarcoma (OSA) is an aggressive and highly malignant tumor of bone with a poor prognosis and it mirrors the disease in humans. Angiogenesis, the formation of new blood vessels, is driven by hypoxia-induced factors such as HIF-1α and VEGF, both of which play a crucial role in tumor growth and metastasis. However, the role of angiogenesis in OSA remains a topic of ongoing debate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!